The Board of Trustees of the Josep Carreras Leukaemia Research Institute, a member of CATALONIA.HEALTH, has approved the appointment of Ari Melnick as the new Director of the centre. Dr Ari Melnick brings extensive experience in haematological research to the Josep Carreras Institute. He graduated in Medicine from the University of Buenos Aires and has worked at prestigious institutions such as the Mount Sinai School of Medicine and the Weill Cornell Cancer Centre, where he has led the “Hematologic Malignancies Program”.
Internationally recognised in the field of haematological diseases and cancer epigenetics, Melnick was among the first to develop rationally designed transcription factor inhibitors and conduct large-scale epigenomic studies in humans. Moreover, he has been awarded the American Society of Haematology Ernest Beutler Award in Translational Research. Melnick serves on the Board of Directors of the Leukaemia and Lymphoma Society and the Lymphoma Research Foundation.
Ari Melnick, new director of the Josep Carreras Leukaemia Research Institute, says: “It is a tremendous honour to be appointed Director of the Josep Carreras Leukaemia Research Institute. In just a short time, the Institute has emerged as a global leader in blood cancer research and is already making a meaningful impact by delivering innovative treatments to patients with leukaemia. As both an oncologist and a scientist, I am confident that the Josep Carreras Institute is poised to build on this remarkable momentum, pioneering new cures and enhancing the quality of life for people affected by haematologic malignancies.”
According to the new Director, “the unique opportunity for translational research here, driven by the Institute’s strong partnerships with Barcelona’s world-class hospitals and research centres, is truly unparalleled. We will continue to find innovative ways to embed scientific research directly into clinical care, ensuring that discoveries move swiftly and seamlessly from bench to bedside. At the same time, we will strengthen our global outlook by establishing strategic collaborations with leading centres across Europe, North and South America, and Asia, harnessing the best science the world has to offer.”
Comments